These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24458108)

  • 1. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
    Okada Y; Miyamoto H; Goji T; Takayama T
    Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer].
    Soeda H; Shimodaira H; Ishioka C
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1079-83. PubMed ID: 21772090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
    Hendifar A; Tan CR; Annamalai A; Tuli R
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.
    Katsila T; Juliachs M; Gregori J; Macarulla T; Villarreal L; Bardelli A; Torrance C; Elez E; Tabernero J; Villanueva J
    Clin Cancer Res; 2014 Dec; 20(24):6346-56. PubMed ID: 25324142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
    Woo J; Palmisiano N; Tester W; Leighton JC
    Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
    Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
    J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
    Troiani T; Zappavigna S; Martinelli E; Addeo SR; Stiuso P; Ciardiello F; Caraglia M
    Expert Opin Biol Ther; 2013 Feb; 13(2):241-55. PubMed ID: 23281932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.
    Giampieri R; Scartozzi M; Del Prete M; Maccaroni E; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Cascinu S
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):272-83. PubMed ID: 23806981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
    Asghar U; Hawkes E; Cunningham D
    Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
    Osera S; Yoshino T
    Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
    Benvenuti S; Sartore-Bianchi A; Di Nicolantonio F; Zanon C; Moroni M; Veronese S; Siena S; Bardelli A
    Cancer Res; 2007 Mar; 67(6):2643-8. PubMed ID: 17363584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
    Misale S; Arena S; Lamba S; Siravegna G; Lallo A; Hobor S; Russo M; Buscarino M; Lazzari L; Sartore-Bianchi A; Bencardino K; Amatu A; Lauricella C; Valtorta E; Siena S; Di Nicolantonio F; Bardelli A
    Sci Transl Med; 2014 Feb; 6(224):224ra26. PubMed ID: 24553387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
    Yang J; Li S; Wang B; Wu Y; Chen Z; Lv M; Lin Y; Yang J
    Tumour Biol; 2016 Sep; 37(9):11645-11655. PubMed ID: 27422777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
    Misale S; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Bardelli A
    Cancer Discov; 2014 Nov; 4(11):1269-80. PubMed ID: 25293556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.